Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DX5T4D
|
|||
| Drug Name |
LY3857210
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Phase 2 | [1] | |
| Company |
Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | P2X purinoceptor 7 (P2RX7) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Reactome | The NLRP3 inflammasome | |||
| WikiPathways | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05630196) Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3857210 for the Treatment of Chronic Low Back Pain. U.S.National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.